MedTrace Logo

A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection

NCT05123599 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-05-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of the study intervention based on hepatitis B surface antigen (HBsAg) levels.

Conditions

  • Hepatitis B, Chronic

Interventions

DRUG

JNJ-73763989

JNJ-73763989 injection will be administered subcutaneously.

BIOLOGICAL

JNJ-64300535

JNJ-64300535 deoxyribonucleic acid (DNA) vaccine injection will be administered intramuscularly.

DRUG

ETV monohydrate

ETV monohydrate film-coated tablets will be administered orally.

DRUG

Tenofovir disoproxil

Tenofovir disoproxil film-coated tablets will be administered orally.

DRUG

TAF

TAF film-coated tablets will be administered orally.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-06
Primary Completion
2023-07-31
Completion
2024-06-26
FDA Drug
Yes

Countries

  • Belgium
  • France
  • Italy
  • New Zealand
  • Poland
  • Spain
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05123599 on ClinicalTrials.gov